nk 92 Search Results


nk92 mi  (ATCC)
96
ATCC nk92 mi
Nk92 Mi, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk92 mi/product/ATCC
Average 96 stars, based on 1 article reviews
nk92 mi - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
nk92 cells  (ATCC)
99
ATCC nk92 cells
Nk92 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk92 cells/product/ATCC
Average 99 stars, based on 1 article reviews
nk92 cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
nk92 cells  (DSMZ)
95
DSMZ nk92 cells
CD99 ligation enhances <t>NK92-mediated</t> cytotoxicity against ALL but not ET cells. Cytotoxicity assays with ALL and ET cells (4–5 for each cell line) were performed with NK92 cells as effectors. Annexin V and 7AAD were used to detect lysed targeted cells. CD99 induced HSP70 (insets in the graphics) and in parallel increased NK92 cytotoxicity against Jurkat ( a ) and Reh ( b ) (3 h of co-incubation) cells. ( c ) Cytotoxicity of NK92 cells against primary BCP-ALL (three independent ETV6/RUNX1-positive cases are shown)
Nk92 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk92 cells/product/DSMZ
Average 95 stars, based on 1 article reviews
nk92 cells - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
nk 92 cells  (Santa Cruz Biotechnology)
85
Santa Cruz Biotechnology nk 92 cells
CD99 ligation enhances <t>NK92-mediated</t> cytotoxicity against ALL but not ET cells. Cytotoxicity assays with ALL and ET cells (4–5 for each cell line) were performed with NK92 cells as effectors. Annexin V and 7AAD were used to detect lysed targeted cells. CD99 induced HSP70 (insets in the graphics) and in parallel increased NK92 cytotoxicity against Jurkat ( a ) and Reh ( b ) (3 h of co-incubation) cells. ( c ) Cytotoxicity of NK92 cells against primary BCP-ALL (three independent ETV6/RUNX1-positive cases are shown)
Nk 92 Cells, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk 92 cells/product/Santa Cruz Biotechnology
Average 85 stars, based on 1 article reviews
nk 92 cells - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier
human nk-92 176v cells  (Conkwest Inc)
90
Conkwest Inc human nk-92 176v cells
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Human Nk 92 176v Cells, supplied by Conkwest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human nk-92 176v cells/product/Conkwest Inc
Average 90 stars, based on 1 article reviews
human nk-92 176v cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cell line nk-92  (Procell Inc)
90
Procell Inc cell line nk-92
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Cell Line Nk 92, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell line nk-92/product/Procell Inc
Average 90 stars, based on 1 article reviews
cell line nk-92 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nk-92  (BioTherapeutics Inc)
90
BioTherapeutics Inc nk-92
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Nk 92, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk-92/product/BioTherapeutics Inc
Average 90 stars, based on 1 article reviews
nk-92 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human nk-92 cells  (Northwell Health Laboratories)
90
Northwell Health Laboratories human nk-92 cells
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Human Nk 92 Cells, supplied by Northwell Health Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human nk-92 cells/product/Northwell Health Laboratories
Average 90 stars, based on 1 article reviews
human nk-92 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
alt-803  (NantKwest)
90
NantKwest alt-803
Sample List of Active Trials Involving Allogeneic NK Cells
Alt 803, supplied by NantKwest, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alt-803/product/NantKwest
Average 90 stars, based on 1 article reviews
alt-803 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nk-92  (ImmunityBio Inc)
90
ImmunityBio Inc nk-92
Sample List of Active Trials Involving Allogeneic NK Cells
Nk 92, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk-92/product/ImmunityBio Inc
Average 90 stars, based on 1 article reviews
nk-92 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nk-92 cell line  (Huashun Flavor Shanghai Co Ltd)
90
Huashun Flavor Shanghai Co Ltd nk-92 cell line
Sample List of Active Trials Involving Allogeneic NK Cells
Nk 92 Cell Line, supplied by Huashun Flavor Shanghai Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk-92 cell line/product/Huashun Flavor Shanghai Co Ltd
Average 90 stars, based on 1 article reviews
nk-92 cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nk-92/5.28.z cells  (Biobeam Scientific)
90
Biobeam Scientific nk-92/5.28.z cells
Sample List of Active Trials Involving Allogeneic NK Cells
Nk 92/5.28.Z Cells, supplied by Biobeam Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nk-92/5.28.z cells/product/Biobeam Scientific
Average 90 stars, based on 1 article reviews
nk-92/5.28.z cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


CD99 ligation enhances NK92-mediated cytotoxicity against ALL but not ET cells. Cytotoxicity assays with ALL and ET cells (4–5 for each cell line) were performed with NK92 cells as effectors. Annexin V and 7AAD were used to detect lysed targeted cells. CD99 induced HSP70 (insets in the graphics) and in parallel increased NK92 cytotoxicity against Jurkat ( a ) and Reh ( b ) (3 h of co-incubation) cells. ( c ) Cytotoxicity of NK92 cells against primary BCP-ALL (three independent ETV6/RUNX1-positive cases are shown)

Journal: Cell Death & Disease

Article Title: CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity

doi: 10.1038/cddis.2012.164

Figure Lengend Snippet: CD99 ligation enhances NK92-mediated cytotoxicity against ALL but not ET cells. Cytotoxicity assays with ALL and ET cells (4–5 for each cell line) were performed with NK92 cells as effectors. Annexin V and 7AAD were used to detect lysed targeted cells. CD99 induced HSP70 (insets in the graphics) and in parallel increased NK92 cytotoxicity against Jurkat ( a ) and Reh ( b ) (3 h of co-incubation) cells. ( c ) Cytotoxicity of NK92 cells against primary BCP-ALL (three independent ETV6/RUNX1-positive cases are shown)

Article Snippet: NK92 cells (from DSMZ) were maintained in X-VIVO 10 medium (Biowhittaker, MD, USA) containing 20% fetal bovine serum ‘Gold' (PAA Laboratories, Pasching, Austria), 200 U/ml interleukin-2 (PeproTech, Vienna, Austria) and supplements.

Techniques: Ligation, Incubation

(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo

doi: 10.1158/1078-0432.CCR-17-1193

Figure Lengend Snippet: (A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Article Snippet: Human NK-92 176V cells were obtained from Conkwest Inc. (San Diego, CA).

Techniques: Imaging, Luciferase, Expressing

Sample List of Active Trials Involving Allogeneic NK Cells

Journal: Transplantation and cellular therapy

Article Title: NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations

doi: 10.1016/j.bbmt.2020.09.030

Figure Lengend Snippet: Sample List of Active Trials Involving Allogeneic NK Cells

Article Snippet: Anderson Cancer Center; National Cancer Institute CB-derived NK cells Rituximab Stem cell transplant Recurrent or refractory B cell non-Hodgkin lymphoma NCT03027128 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Metastatic of locally advanced solid tumors NCT03068819 Washington University School of Medicine Cytokine-induced memory-like NK cells CD3 + T cells donor lymphocyte infusion Relapsed AML NCT03136406 NantKwest, Inc. NK92 cell line ALT-803 Other immune modulators Pancreatic cancer NCT03167164 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Merkel cell carcinoma NCT03167177 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Melanoma NCT03169738 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Non-small-cell lung cancer NCT03169764 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Head and neck squamous cell carcinoma NCT03169777 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Colorectal cancer NCT03169790 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Non-Hodgkin lymphoma NCT03175666 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Triple-negative breast cancer NCT03197571 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Urothelial carcinoma NCT03197584 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Ovarian cancer NCT03300492 University Hospital, Basel, Switzerland Haploidentical NK cells Acute myeloid leukemia; myelodysplastic syndromes NCT03329248 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Pancreatic cancer NCT03383978 Johann Wolfgang Goethe University Hospital NK92 cell line gene modified to express anti-Her2 CAR-expressing CD28 and ζ Glioblastoma NCT03387085 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Triple-negative breast cancer NCT03387098 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Pancreatic cancer NCT03387111 NantKwest, Inc. NK92 cell line modified to express IL-2 and CD16 (haNK) Other immune modulators Squamous cell carcinoma NCT03415100 The Third Affiliated Hospital of Guangzhou Medical University Autologous or allogeneic NK cells transfected with mRNA expressing NKG2D-directed CAR Metastatic solid tumors NCT03420963 M.D.

Techniques: Transplantation Assay, Modification, Transfection, Expressing, Derivative Assay